CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

The Vanguard US Total Market Shares Index ETF (ASX: VTS) outperformed the Vanguard Australian Shares Index ETF (ASX: VAS) by ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

ETFs across various categories pulled in $17.7 billion in capital last week, pushing year-to-date inflows to more than $27 billion. U.S. fixed-income ETFs led the way with inflows of $7.2 billion, ...

The top 10 holdings account for about 56.78% of total assets under management. VUG seeks to match the performance of the CRSP U.S. Large Cap Growth Index before fees and expenses. The CRSP US Large ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

瑞士楚格和波士顿 - 目前股价为$39.69，市值33.9亿美元的CRISPR Therapeutics (NASDAQ:CRSP)宣布了其2025年战略重点，专注于继续推出其基因药物CASGEVY®以及几个关键开发项目的更新。公司以强劲的资产负债表开始新的一年，拥有约19亿美元的现金、现金等价物和可销售证券。

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...